饮食质量和帕金森病:非运动性症状管理的潜在策略
Dayoon Kwon1, Aline D Folle1, Irish Del Rosario1
1Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Parkinsonism & related disorders
|August 23, 2023
概括
帕金森病患者的饮食质量比对照患者差. 饮食改变可能有助于管理非运动症状,如帕金森病 (PD) 中的便秘.
科学领域:
- 神经学 神经学
- 营养科学 营养科学
- 流行病学 流行病学
背景情况:
- 帕金森病 (PD) 越来越被认为是一种全身性疾病.
- 饮食因素可能会影响PD表型和进展.
- 了解PD的饮食质量对于管理至关重要.
研究的目的:
- 为了比较PD患者和对照者的饮食质量和营养摄入量.
- 调查饮食和PD临床特征之间的关联,包括症状和药物使用.
主要方法:
- 一项涉及98名PD患者和83名中部加利福尼亚州对照者的病例控制研究.
- 使用健康饮食指数 (HEI) -2015评估过去一个月的饮食习惯.
- 多变量逻辑和线性回归分析调整为混因子.
主要成果:
- 与对照组相比,PD患者的HEI-2015得分较低.
- 在PD患者中,质量较差的饮食与较高的碳水化合物,糖和反式脂肪摄入量以及较低的纤维,叶酸,不和脂肪酸,蛋白质和脂肪摄入量有关.
- 在PD患者中,便秘与显著较低的HEI得分相关,较高的多巴胺激动剂剂与糖消耗增加有关.
结论:
- 患有PD的患者通常食用的饮食质量低于非PD患者.
- 饮食干预可以改善非运动症状,例如在PD中便秘.
- 建议在PD管理中促进健康饮食,特别是对于服用多巴胺激动剂或患有低血的患者.
相关概念视频
Parkinson's Disease: Treatment
297
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
297
Parkinson's Disease: Overview
596
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
596
Chronic Kidney Disease III: Interprofessional Care
42
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
42
Peritoneal Dialysis III: Nursing Management
45
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
45
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
355
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
355
Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213


